AgeneBio Receives Grant for Drug-Discovery Program Targeting Cognitive Decline in Alzheimer’s

AgeneBio Receives Grant for Drug-Discovery Program Targeting Cognitive Decline in Alzheimer’s
AgeneBio has received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of a novel GABAdiscovery program targeting hippocampal overactivity in the brain, which is thought to contribute to neurodegeneration and cognitive decline in Alzheimer’s disease (AD) patients. AgeneBio’s pipeline of therapies is based on research showing that overactivity in the hippocampus (the part of the brain responsible for emotion, memory, and learning) contributes to cognitive impairment and drives neurodegeneration later on. This overactivity is characteristic of mild cognitive impairment (MCI) due to AD, the symptomatic pre-dementia stage before AD fully develops. AgeneBio’s lead candidate, AGB101, is now ready to enter Phase 3 development. If approved, it will be the first therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow down progression and delay onset of AD’s dementia. "AgeneBio's GABA-A discovery program is a novel approach to delaying the onset of Alzheimer's dementia by targeting the marked hippocampal overactivity that is present during MCI due to AD," Sharon Rosenzweig-Lipson, PhD, said in a press release. Rosenzweig-Lipson is primary investigator on studies supported by this grant and AgeneBio’s vice president of research and development. "We are very grateful to the ADDF, a leader in supporting Alzheimer's res
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *